Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE).

Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Malaya
• Treatments: Bevacizumab; Endothelial Growth Factors; Glucuronyl glucosamine glycan sulfate; Ranibizumab

Criteria

Inclusion Criteria:

• Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease

Exclusion Criteria:

• History of previous systemic or ocular Anti-VEGF therapy

• History of previous intravitreal injection with any drug

• Intraocular pressure ≥ 22

• Glaucoma

• History or presence of thromboembolic events

• Un-controlled blood pressure

• Blood donation during the previous 3 weeks

• Relevant media opacity of the lens